Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.04 USD

83.04
5,653,121

+0.83 (1.01%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $83.05 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Alkermes Initiates Rolling Submission of Depression Drug

Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.

    Arpita Dutt headshot

    4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings

    Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.

      Alexion's (ALXN) Soliris' Label Expansion Approved in Europe

      Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.

        Mylan Finalizes Settlement Agreement with DOJ for $465M

        Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.

          AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

          AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

            Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

            Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

              Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning

              Pfizer, Inc.'s (PFE) leukemia candidate, Besponsa received FDA approval, though with a boxed warning on the label.

                Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial

                Regeneron Pharmaceuticals, Inc. (REGN) announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab .

                  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

                  Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review

                    This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.

                      Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research

                      Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research

                        Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak

                        Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.

                          Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences

                          Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences

                            Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

                            Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

                              5 Discounted PEG Stocks for GARP Investors

                              PEG ratio is categorized under value investing and follows the principles of both growth and value investing.

                                Arpita Dutt headshot

                                Forget Teva (TEVA), Buy These 4 Drug Stocks Instead

                                With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.

                                  Supriyo Bose headshot

                                  Markets Remain Choppy on Continuing Conflicts: 5 Top Picks

                                  ROE helps investors distinguish between profit-generating companies from profit burners and is useful for determining the financial health of a company.

                                    Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss

                                    Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.

                                      Top Ranked Income Stocks to Buy for August 10th

                                      Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 10th:

                                        Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View

                                        Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.

                                          Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View

                                          Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.

                                            Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

                                            Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

                                              Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak

                                              Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.

                                                Arpita Dutt headshot

                                                Forget Bayer, Buy These 3 Drug Stocks Instead

                                                With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.

                                                  Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

                                                  A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.